As has been suggested previously [22], the ability of allosteric AMPK activators to stimulate non-pThr172 complexes could be highly significant in terms of potential therapeutic strategies for activating AMPK, particularly those diseases where there is a lack of upstream AMPK kinase activity, such as loss of LKB1 in certain cancers [41]. Here, PRKAA2 is linked to cancer.